

ACT for ALS

TWO BILLS -- H.R.8662 AND S.4876

House of
Representatives bill
H.R.8662

Senate bill
S.4876

WHAT DOES THE BILL DO?



Increase the opportunity for patients to access investigational therapies outside of clinical trials. These patients may not live long enough to benefit from a drug eventually being approved.





The bill takes efforts to enrich the development of these therapies. It also works to streamline the review and approval of effective therapies to treat neurodegenerative diseases.

SCORE

WAIT ... WASN'T THERE ALREADY THIS BILL IN THE HOUSE?
YOU'RE RIGHT!


WHAT'S NEW ABOUT THIS ONE?

Thanks for asking. There are three components that have different aspects in the new bill.



It creates a grant program that now funds research on -- in addition to access to -- investigational ALS treatments being tested from small biopharmaceutical companies to patients not participating in the clinical trial.

It establishes a Health and Human Services (HHS) Collaborative for Neurodegenerative Diseases now jointly led by the FDA and the National Institutes of Health (NIH). This is the first (!!!) federal effort explicitly charged with the responsibility to speed the development and approval of therapies for neurodegenerative diseases.



It develops an FDA grant program which funds research on and development of interventions to prevent, diagnose, treat or cure ALS and other life-threatening or severely debilitating neurodegenerative diseases.



TAKE ACTION

Help build congressional support by contacting your elected official to support ACT for ALS

[Click Here To Change History](#)